Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TIGER 1: A Randomized, Open-Label, Phase 2/3 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients With EGFR-Mutant Advanced/Metastatic NSCLC

NCT02186301 is registered in ClinicalTrials.gov with Clovis Oncology, Inc. as lead sponsor.

NCT NCT02186301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02186301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TIGER 1: A Randomized, Open-Label, Phase 2/3 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients With EGFR-Mutant Advanced/Metastatic NSCLC
Lead sponsor
Clovis Oncology, Inc.
Phase
Phase 2/3
Overall status
Terminated
Start date
November 30, 2014
Completion date
June 28, 2017
Enrollment
100 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer